We agree with Dr Mehta that anti-inflammatory properties of thalidomide may play a role in its antimyeloma effect. 1 As mentioned in our report, 2 there are several hypothesized mechanisms of action postulated for thalidomide, including effects on tumor cell growth and apoptosis, angiogenesis, cytokines that mediate inflammation, the immune system, and adhesion molecules. The precise mechanism of action of thalidomide has been difficult to elucidate because of its relative lack of activity in in vitro assays compared to effects in vivo, and the fact that, in solutions at physiologic pH (including blood plasma), it undergoes spontaneous nonenzymatic hydrolysis into 12 or more metabolites. 3, 4 We have studied a variety of cytokines including TNFa and IL-6 in the context of thalidomide therapy. Our findings suggest that patients with higher pretreatment plasma levels of TNFa may have an inferior progression-free survival with thalidomide therapy (alone or in combination with dexamethasone) for newly diagnosed myeloma. 5 We also find that patients with an increase in plasma IL-6 levels post-therapy may have inferior progression-free survival compared to patients whose levels stay stable or decrease with therapy. In contrast, plasma levels of angiogenic cytokines VEGF and bFGF did not predict response to therapy or change significantly following therapy in our study. These results are preliminary, but support Dr Mehta's point that the mechanism of action of thalidomide in myeloma may include anti-inflammatory effects.
We also agree with Dr Mehta that there is a need to study the role of anti-inflammatory agents in the progression of myeloma. For instance, there are data that IL-1b, a key mediator of inflammation, is involved in the progression of asymptomatic myeloma to symptomatic disease. 6 A clinical trial using an IL-1 receptor antagonist to prevent the progression of early-stage myeloma is now ongoing at the Mayo Clinic. 
TO THE EDITOR
The mitogen-activated protein kinase (MAPK) pathway is a highly conserved pathway that regulates proliferation, differentiation, survival and apoptosis in many eucaryote cells and organisms.
Mutations of the genes encoding key components of MAPK pathway contribute to the development of several human cancers. 1 RAF genes encode serine-threonine kinases, which transduce regulatory signals from RAS to MEK1/2. All RAF isoforms (RAF1, BRAF and ARAF) share RAS as a common upstream activator. 2 Recently, great interest has grown about mutations in the BRAF gene that have been described in more than 60% of malignant melanomas, in 10% of colorectal cancers and in a small percentage of many other human tumors. [3] [4] [5] Most frequently mutations of BRAF gene arise within the kinase domain as a single base replacement (T1796A) in exon 15, leading to the substitution of valine by glutamic acid (V599E). This is by far the most common mutation, accounting for about 80% of all cases. This mutation causes the constitutional activation of the kinase and its downstream effectors. Activating mutations were recently found in many neoplasms that harbor wild-type RAS, 3 including colon carcinomas. 4 Thus, RAS and BRAF mutations appear to be mutually exclusive. Nonetheless, both result in the constitutive activation of MAPK pathway in human tumors.
We have previously demonstrated that in multiple myeloma (MM) and plasma cell leukemia (PCL), the activation of the MAPK pathway is associated with disease progression and adverse prognostic parameters. 6 MAPK activation in MM (9%) and PCL (31%) is due to the high rate of mutations of the N-and K-RAS genes (codons 12, 13 and 61). These findings have been confirmed by other investigators.
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Since a considerable fraction of MM and PCL do not carry detectable RAS mutations, we screened exon 15 for the most common BRAF mutations (amino-acid positions 596 and 599) in bone marrow samples from patients with PCL or MM that we have previously characterized for N-and K-RAS mutations. 6 In total, 100 ng of genomic DNA were subjected to single-step PCR (30 s at 941C, 30 s at 581C and 30 s at 721C for 33 cycles) using primers designed to amplify the exon 15 of BRAF gene.
3 PCR products were purified, directly sequenced using the BigDye Terminator Cycle Sequencing Ready Reaction Kit and analyzed on an ABI 310 automated capillary system (Applied Biosystems). The sensitivity of this sequencing approach was established by serially diluting (50, 25, 12.5, 6.25 and 3%) A2058 melanoma cells (a positive control carrying the T1796A mutation) with K562 cells (a leukemic cell line with wild-type BRAF) (Figure 1 ). Since we reliably detected the BRAF mutation when at least 6.25% of mutated cells were present in the tested DNA sample, we studied a total of 65 fresh bone marrow samples from 18 patients with PCL and 47 patients with MM at diagnosis, in which neoplastic plasma cells were greater than 20% of the total cells.
No BRAF mutations in position 596 and 599 were identified in both groups of 52 patients that harbor wild-type N-or K-RAS as well as in the group of 8 patients carrying mutations in N-or K-RAS (Table 1) .
Overall, these data demonstrate that BRAF mutations within the exon 15 of the gene are not detectable, or very low, in MM and PCL regardless of the presence of mutations in N-or K-Ras gene. Similar data have been recently reported for other hematopoietic malignancies such as acute myelogenous leukemia. 8 These findings suggest that in plasma cell neoplasms molecules other than BRAF may elicit the activation of the MAPK pathway or that alternative pathways could have more important role in the development and progression of the disease. 
TO THE EDITOR
The BCL10 gene, originally identified through its recurrent involvement in t(1;14)(p22;q32) of the mucosa-associated lymphoid tissue (MALT) lymphoma, encodes a cytosolic protein composed of 233 amino-acid residues with proapoptotic and proinflammatory activities, whereas mutated BCL10, causing Cterminal truncation, can operate as an oncogene. 1 BCL10 is widely expressed in normal lymphoid tissues, with the expression level depending on the developmental stage of lymphocytes.
2 Many B-cell lymphomas, including MALT lymphoma, also express BCL10. 2 In contrast to the normal B cells that express BCL10 in the cytoplasm, MALT lymphoma cells with t(1;14)(p22;q32) or t(11;18)(q21;q21) translocation express the protein predominantly in the nucleus.
2-4 Recently, we reported that BCL10 is expressed in the cytoplasm of normal NK cells, and demonstrated its aberrant nuclear localization in the tumor cells of nasal NK/T-cell lymphomas (NL). 5 Many NL tumors have the same nuclear staining of BCL10 as the MALT lymphomas, but the chromosomal translocations t(1;14)(p22;q32) or t(11;18)(q21;q21) that are the hallmark of MALT lymphoma [2] [3] [4] are not present in NL, 6 implicating an alternative mechanism leading to aberrant BCL10 nuclear localization during tumorigenesis of NL. 5 In this study, we examined BCL10 gene mutations in normal NK cells and NL, and investigated whether these mutations were associated with the aberrant BCL10 localization in the nucleus in NL.
þ normal NK cells were isolated from the peripheral blood mononuclear cells (PBMC) of two healthy volunteers by cell sorting using an EPICS ALTRA cell sorter (Beckman Coulter, Miami, FL, USA). Frozen tumor blocks of 18 NL cases and 13 paraffin blocks of these cases were retrieved from the Department of Pathology, Queen Mary Hospital, the University of Hong Kong, Hong Kong. Lymphomas were diagnosed according to the World Health Organization (WHO) classification of lymphoid malignancies, as reported previously. 0 were included in the reaction to amplify a 1005 bp cDNA fragment of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the internal control. RNA from 10 reactive tonsils served as positive control, whereas distilled water served as negative control. The purified PCR products were directly sequenced from both directions.
BCL10 mRNA expression was detected by RT-PCR in normal NK cells (Figure 1a ) and 16 of 18 (89%) NL cases (Figure 1c) . No mutations were detected in the BCL10 cDNA sequences from the NK cells. However, among the 16 NL informative cases in which the full-length coding sequence could be amplified, a total of eight extra electrophoretic bands of PCR products ranging from 150 to 700 bp were observed in six cases, raising the possibility that partial sequence deletion within the BCL10 gene or altered pre-mRNA splicing might have occurred in these NL cases. As a control, RT-PCR of the RNA from 10 reactive tonsils was used, following the same protocol, which showed only wild-type PCR products (Figure 1b) . The BCL10 cDNA sequences from the reactive tonsils were also analyzed and no mutations were detected.
DNA sequencing from the aberrant PCR products identified four types of variants, three deletion variants in two cases ( Figure 2a ) and one pattern of splicing transcripts missing the first 33 bp in the coding exon 3 sequence in five cases (Figure 2c) . Sequencing of the normal-sized RT-PCR products showed only three known single-nucleotide polymorphisms at nucleotides 13, 24 and 638. 7 To confirm the finding of 224 bp deletion in the cDNA sequences from case 7, the DNA from the same case was examined by PCR with primers 5 0 -TGAAAAACTGAGGGCATC-CA-3 0 and 5 0 -CATTAAAAATTAAAAGGCAATAAAGTG-3 0 (nucleotides 14177-14474 GenBank accession no. AF097732). Deletion D224 was detectable in the genomic DNA sample verifying the sequencing data derived from the mRNA (Figure 2b) .
Among the five cases that had 33 bp splicing variants, NL case number 14 had a relatively strong 33 bp splice variant but only a very faint wild-type BCL10 mRNA, in contrast to the other four tumors (Figure 1c) . To determine whether 33 bp splicing is caused by mutation, the genomic DNA sequence spanning the intron 2 and coding exon 3 boundary from the related tumors was amplified by PCR with primers 5 0 -TTAACAAGTCACAA GATGGACAGTG-3 0 and 5 0 -CTAGAACAGGCAAATTCAGA
